Drug intelligence / Profile preview

GCF20215

Development stage: Preclinical
Lead developer: Guangzhou Green Cross Pharmaceutical
Modality: Small Molecules

Overview

GCF20215 (also known as GCA1004) is an anti-infective drug candidate being developed by Guangzhou Green Cross Pharmaceutical. It is classified as both a new chemical entity (GCA1004) and an innovative formulation (GCF20215). The drug is intended for the treatment of chronic soft tissue infections, chronic folliculitis, and abscesses. It is currently in the IND-enabling stage (申报临床) in China, representing a key part of the company's anti-infection pipeline. The project utilizes a small molecule approach combined with a novel delivery formulation to address persistent dermatological and soft tissue infections.

Beyond the preview

Go deeper on GCF20215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCF20215.

Explore the full profile